Combination therapy is the use of two or more therapies with the intention of improving patient health which are increasingly becoming more prevalent in the health system. Combination therapies can be produced by a single manufacturer but often the various components of the combination are produced by different companies which creates complexities in terms of pricing and reimbursement arrangements. This is a growing area of policy attention internationally with countries taking different paths to addressing the problem. The Institute of Health Economics conducted a workshop in 2022 to examine a path forward to create a made-in-Canada approach and outlining some foundational activities required to be prepared to address this issue. The webinar will outline the key findings from the workshop.

For more information and to register click here.